TY - JOUR
TI - Antidiabetic drugs and blood pressure changes
AU - Ilias, I.
AU - Thomopoulos, C.
AU - Michalopoulou, H.
AU - Bazoukis, G.
AU - Tsioufis, C.
AU - Makris, T.
JO - Pharmacology Research and Perspectives
PY - 2020
VL - 161
TODO - null
SP - null
PB - INSTAP Academic Press
SN - null
TODO - 10.1016/j.phrs.2020.105108
TODO - aleglitazar;  antidiabetic agent;  antihypertensive agent;  canagliflozin;  chlorpropamide;  dipeptidyl peptidase IV inhibitor;  glibenclamide;  gliclazide;  glimepiride;  glipizide;  glitazone derivative;  glucagon like peptide 1 receptor agonist;  glucose;  hemoglobin A1c;  insulin;  insulin glargine;  linagliptin;  metformin;  peroxisome proliferator activated receptor gamma agonist;  pioglitazone;  placebo;  sodium glucose cotransporter 2 inhibitor;  sulfonylurea derivative;  antidiabetic agent;  biological marker;  dipeptidyl peptidase IV inhibitor;  incretin, all cause mortality;  antidiabetic activity;  antihypertensive activity;  blood glucose monitoring;  blood pressure;  blood pressure regulation;  body weight;  cardiovascular disease;  cardiovascular mortality;  cardiovascular risk;  cerebrovascular accident;  diabetes mellitus;  diastolic blood pressure;  disease association;  drug mechanism;  drug safety;  elevated blood pressure;  heart failure;  human;  hyperinsulinemia;  hypertension;  hypokalemia;  impaired glucose tolerance;  incidence;  ischemic heart disease;  non insulin dependent diabetes mellitus;  nonhuman;  pathophysiology;  pressor response;  priority journal;  Review;  risk reduction;  systolic blood pressure;  vasodilatation;  blood;  blood pressure;  cardiovascular disease;  diabetes mellitus;  drug effect;  glucose blood level;  meta analysis;  metabolism;  randomized controlled trial (topic);  treatment outcome, Biomarkers;  Blood Glucose;  Blood Pressure;  Cardiovascular Diseases;  Diabetes Mellitus;  Dipeptidyl-Peptidase IV Inhibitors;  Humans;  Hypoglycemic Agents;  Incretins;  Randomized Controlled Trials as Topic;  Sodium-Glucose Transporter 2 Inhibitors;  Treatment Outcome
TODO - New era antidiabetic drugs are characterized by cardiovascular safety, including specific outcome benefits observed in randomized clinical trials (RCTs). It has been postulated that the favorable effects of new antidiabetic agents are related both to better control of blood pressure (BP) levels and to activation of multiple anti-atherosclerotic properties. In this review, we aimed to assess whether antidiabetic drugs have a pressor effect in glucose control and outcome-oriented RCTs, and to summarize the activated pathophysiological mechanisms relevant to BP control following the use of different antidiabetic drug classes. We also tried to determine which, if any, are the BP-lowering effects of more intense vs less intense glucose-lowering strategy irrespectively of trial antidiabetic regimen. To provide more robust results and evidence-based argumentation, a meta-analysis of placebo-controlled antidiabetic drug RCTs was undertaken to estimate the ongoing BP reduction for all considered and each separate drug class alone. This quantitative synthesis might be helpful for the clinician 1) to select or avoid the use of some classes of antidiabetic agents with a potential favorable or adverse pressor effect, respectively 2) to organize the overall drug regimen in patients with diabetes mellitus and minimize side effects because of concomitant use of drugs with established pressor effect (i.e. antihypertensive agents). This review was also organized to indicate whether BP change associated with different antidiabetic treatments may explain the specific macrovascular outcome benefits. Between all antidiabetic drugs including exogenous insulin, only sodium-glucose cotransporter 2 inhibitors produce a clinically important BP-lowering effect, but this BP reduction alone cannot explain the observed cardiovascular benefit. © 2020 Elsevier Ltd
ER -